The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2024 | ‘Clinical case discussions’ session rundown: HLH/MAS, aseptic meningitis, & CAR-NK cells in MM
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, shares an insight into a clinical case session held at the CAR-T Meeting 2024. In this session, three clinical cases were presented. The first was a pediatric patient with B-cell acute lymphoblastic leukemia (B-ALL) presenting with hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following CAR T-cell infusion. The second was a patient with mantle cell lymphoma (MCL) presenting with recurrent immune effector cell-associated neurotoxicity syndrome (ICANS) and aseptic meningitis following CD19 CAR-T therapy. Dr Popat highlights that this prompted a debate on the use of chemotherapy for the management of ICANS following CAR-T. Finally, the third case dealt with the use of cord-blood derived allogeneic natural killer (NK) cells in conjunction with CAR-NK cells for the treatment of a patient with multiple myeloma (MM). This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: GSK
Honoraria: GSK, Janssen, BMS, AbbVie, Roche
Research Funding: GSK
Current Employment: University College London Hospitals NHS Foundation Trust.
